Dr. Daniel Drucker, a leading researcher at the University of Toronto, has weighed in on the expanding potential of GLP-1 receptor agonists, a class of drugs best known for treating type 2 diabetes and obesity. In a recent interview, Drucker highlighted emerging research suggesting these medications could be effective for a range of other conditions, including cardiovascular disease, liver disease, and even addiction.
Beyond Diabetes and Weight Loss
GLP-1 drugs, such as semaglutide and liraglutide, work by mimicking a hormone that regulates blood sugar and appetite. However, new studies indicate they may also reduce inflammation and improve heart health. Drucker noted that trials have shown significant benefits in reducing heart attacks and strokes in patients with obesity, independent of weight loss.
Potential for Liver and Kidney Diseases
Research is also exploring the use of GLP-1 drugs for non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease. Early results suggest these drugs can reduce liver fat and improve kidney function, offering new hope for patients with limited treatment options.
Addiction and Neuroprotection
Perhaps most surprising is the potential for GLP-1 drugs to treat addiction. Animal studies have shown they can reduce cravings for alcohol and opioids. Drucker emphasized that while human trials are needed, the mechanism is plausible given the drugs' effects on brain reward pathways.
Drucker cautioned that more research is necessary before these uses become standard practice, but the future looks promising. He stressed the importance of long-term safety studies, especially as these drugs are prescribed to broader populations.
